Estrogen replacement therapy, atherosclerosis, and vascular function

Cardiovascular Research

Volumn 53, Issue 3, 2002, Pages 605-619

  Mikkola, Tomi S ^a,b   Clarkson, Thomas B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Atherosclerosis; Endothelial function; Hormones; Infection inflammation; Lipid metabolism

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; GESTAGEN; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; MONKEY; NONHUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGING; ANIMALS; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; INFLAMMATION; ISOFLAVONES; LIPIDS; MACACA; MALE; MIDDLE AGED; MODELS, ANIMAL; PHYTOESTROGENS; PLANT PREPARATIONS; PROGESTINS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037084151     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00466-7     Document Type: Article

References (143)

1. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men
2. Estrogen and coronary heart disease in women
3. Women and heart disease
4. Menopause and risk of cardiovascular disease: The Framingham study
5. Smoking and age at menopause in women
6. Menopause and the risk of coronary heart disease in women
7. Age at natural menopause and risk of cardiovascular disease
8. Does age at natural menopause affect mortality from ischemic heart disease?
9. Age at menopause as a risk factor for cardiovascular mortality
10. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromso Study
11. Hormone therapy to prevent disease and prolong life in postmenopausal women
12. Hormone replacement therapy, heart disease, and other considerations
13. A prospective study of postmenopausal estrogen therapy and coronary heart disease
14. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
15. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
16. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
17. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
18. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies?
19. The relationship of treatment adherence to the risk of death after myocardial infarction in women
20. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project
21. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution
22. Hormone replacement therapy and coronary artery atherosclerosis: The monkey model
23. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone
24. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
25. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
26. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
27. Design of the Women's Health Initiative clinical trial and observational study
28. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
29. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys
30. Inhibition of postmenopausal atherosclerosis progression: A comparison of the effects of conjugated equine estrogens and soy phytoestrogens
31. Regression of atherosclerosis in female monkeys
32. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
33. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement
34. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
35. Tibolone does not stimulate the endometrium or breast in cynomolgus monkeys
36. Lipoprotein-cholesterol distributions in selected North American populations: The lipid research clinics program prevalence study
37. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults
38. Risk factors that attenuate the female coronary disease advantage
39. Influence of age and menopause on serum lipids and lipoproteins in healthy women
40. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
41. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
42. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
43. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
44. Lipoprotein(a) as a determinant of coronary heart disease in young women
45. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration
46. Effects on serum lipid profiles of continuous 17-beta-estradiol, intermittent norgestimate regimens versus continuous combined 17-beta-estradiol/norethisterone acetate hormone replacement therapy
47. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate
48. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins
49. Transdermal administration of oestrogen/progestagen hormone replacement therapy
50. Biologic effects of transdermal estradiol
51. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
52. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
53. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
54. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
55. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia
56. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease
57. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
58. The protective effects of estrogen on the cardiovascular system
59. Cloning of the human estrogen receptor cDNA
60. Cloning of a novel receptor expressed in rat prostate and ovary
61. Human vascular smooth muscle cells contain functional estrogen receptor
62. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function
63. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta
64. Estrogen receptors alpha and beta: Prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects
65. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta
66. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice
67. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice
68. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/-mice
69. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene
70. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man
71. Chronic and acute effects of oestrogens on vascular contractility
72. Estrogen modulates responses of atherosclerotic coronary arteries
73. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries
74. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy
75. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
76. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
77. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women
78. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women
79. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women
80. Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow
81. Estrogen and postmenopausal estrogen/progestin therapy: Effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production
82. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1
83. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women
84. Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women
85. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane
86. Estrogen increases endothelial nitric oxide by a receptor-mediated system
87. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium
88. 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells
89. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium
90. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor
91. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen
92. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism
93. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit
94. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions
95. Pathogenesis of atherosclerosis
96. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys
97. Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys
98. Oral contraceptive treatment decreases arterial low density lipoprotein degradation in female cynomolgus monkeys
99. 17beta-estradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation
100. Aortic permeability to LDL during estrogen therapy-a study in normocholesterolemic rabbits
101. Atherosclerosis - An inflammatory disease
102. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
103. Hormone replacement therapy, inflammation, and hemostasis in elderly women
104. Hormone replacement therapy and increased plasma concentration of C-reactive protein
105. Effect of postmenopausal hormones on inflammation-sensitive proteins
106. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
107. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study
108. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease
109. Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules
110. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management
111. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis
112. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1
113. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression
114. Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study
115. Selective estrogen receptor modulators: Clinical spectrum
116. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
117. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
118. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
119. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys
120. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates
121. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
122. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
123. Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention?
124. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
125. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
126. Risk of acute coronary events according to serum concentrations of enterolactone: A prospective population-based case-control study
127. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys
128. Meta-analysis of the effects of soy protein intake on serum lipids
129. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins
130. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women
131. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques
132. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women
133. Pharmacological studies with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org O.D. 14)
134. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
135. Tibolone: Prevention of bone loss in late postmenopausal women
136. Org OD 14 and the endometrium
137. A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women
138. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women
139. Tibolone: Influence on markers of cardiovascular disease
140. Cholesterol efflux potential of serum from atherogenic diet-fed cynomolgus monkeys after long-term tibolone treatment or traditional hormone replacement therapy
141. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques
142. Dietary soy phytoestrogens inhibit tumor promotion by exogenous but not endogenous estrogens in the rat DMBA model of mammary carcinogenesis
143. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys